After entering the muscle cell, glucose is immediately and irreversibly phosphorylated to glucose-6-phosphate by hexokinases (HK) I and II. Previous studies in rodents have shown that HKII may be the dominant HK in skeletal muscle. Reduced insulin-stimulated glucose uptake and reduced glucose-6-phosphate concentrations in muscle have been found in non-insulin-dependent diabetes mellitus (NIDDM) patients when examined during a hyperglycemic hyperinsulinemic clamp. These findings [correction of finding] are consistent with a defect in glucose transport and/or phosphorylation. In the present study comprising 29 NIDDM patients and 25 matched controls, we tested the hypothesis that HKII activity and gene expression are impaired in vastus lateralis muscle of NIDDM patients when examined in the fasting state. HKII activity in a supernatant of muscle extract accounted for 28 +/-5% in NIDDM patients and 40 +/-5% in controls (P = 0.08) of total muscle HK activity when measured at a glucose media of 0.11 mmol/liter and 31 +/-4 and 47 +/-7% (P = 0.02) when measured at 0.11 mmol/liter of glucose. HKII mRNA, HKII immunoreactive protein level, and HKII activity were significantly decreased in NIDDM patients (P < 0.0001, P = 0.03, and P = 0.02, respectively) together with significantly decreased glycogen synthase mRNA level and total glycogen synthase activity (P = 0.02 and P = 0.02, respectively). HKII activity in a supernatant of muscle extract accounted for 28±5% in NIDDM patients and 40±5% in controls (P = 0.08) of total muscle HK activity when measured at a glucose media of 0.11 mmol/liter and 31±4 and 47±7% (P = 0.02) when measured at 11.0 mmol/liter of glucose. HKII mRNA, HKII immunoreactive protein level, and HKII activity were significantly decreased in NIDDM patients (P < 0.0001, P = 0.03, and P = 0.02, respectively) together with significantly decreased glycogen synthase mRNA level and total glycogen synthase activity (P = 0.02 and P = 0.02, respectively). In the entire study population HKII activity estimated at 0.11 and 11.0 mM glucose was inversely correlated with fasting plasma glucose concentrations (r = -0.45, P = 0.004; r = -0.54, P < 0.0001, respectively) and fasting plasma nonesterified fatty acid concentrations (r = -0.46, P = 0.003; r = -0.37, P = 0.02, respectively). In conclusion, NIDDM patients are characterized by a reduced activity and a reduced gene expression of HKII in muscle which may be secondary to the metabolic perturbations. HKU contributes with about one-third of total HK activity in a supernatant of human vastus lateralis muscle. (J. Clin. Invest. 1995. 96:2639-2645
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HKII activity in a supernatant of muscle extract accounted for 28±5% in NIDDM patients and 40±5% in controls (P = 0.08) of total muscle HK activity when measured at a glucose media of 0.11 mmol/liter and 31±4 and 47±7% (P = 0.02) when measured at 11.0 mmol/liter of glucose. HKII mRNA, HKII immunoreactive protein level, and HKII activity were significantly decreased in NIDDM patients (P < 0.0001, P = 0.03, and P = 0.02, respectively) together with significantly decreased glycogen synthase mRNA level and total glycogen synthase activity (P = 0.02 and P = 0.02, respectively). In the entire study population HKII activity estimated at 0.11 and 11.0 mM glucose was inversely correlated with fasting plasma glucose concentrations (r = -0.45, P = 0.004; r = -0.54, P < 0.0001, respectively) and fasting plasma nonesterified fatty acid concentrations (r = -0.46, P = 0.003; r = -0.37, P = 0.02, respectively). In conclusion, NIDDM patients are characterized by a reduced activity and a reduced gene expression of HKII in muscle which may be secondary to the metabolic perturbations. (1) . Hexokinases I, II, and III share several properties including a molecular mass of -100 kD, a high affinity for glucose, and inhibition by the reaction product glucose-6-phosphate (G6P) (2) . HKIV, commonly referred to as glucokinase, has a molecular mass of 50 kD and is primarily located in liver and pancreatic /3 cells, has a lower affinity for glucose, and is not subject to feedback regulation by G6P (3) .
From previous studies in rodents it has been shown that HKII predominates in muscle tissue where it is found in particular in a mitochondrial-free, sarcoplasmatic vesicle-rich fraction and it has been proposed that HKII may function in muscle mainly to aid glycogen production ( 1, 4) . Moreover, studies of streptozotocin diabetic rats have shown decreased activity of gastrocnemius muscle HKII, possibly due to a loss in the amount of HKII protein rather than to an inhibition by G6P or other metabolites (5) . Furthermore, within 2 h after insulin administration to diabetic rats net HK activity was restored to normal values, suggesting that insulin could be involved in the regulation of HKII synthesis (5) .
Under clamp conditions of euglycemia and hyperinsulinemia, glucose clearance in patients with non-insulin-dependent diabetes mellitus (NIDDM) is characteristically decreased by 30-50% with glucose storage being the quantitatively most affected pathway (6) . Muscle glucose transport and glycogen synthesis are both insulin-stimulated pathways and each has separately been suggested to be responsible for the reduced rate of insulin-stimulated glucose disposal in NIDDM patients. Thus, impaired insulin-stimulated 3-O-methylglucose transport in muscle strips isolated from NIDDM patients has been reported (7, 8) . Furthermore, studies in healthy volunteers and insulin-dependent diabetic subjects show that glucose transport in muscle may be rate-limiting for overall glucose disposal over a wide range of plasma insulin and glucose levels (9, 10). In patients with long-term NIDDM, in vivo measurement of the muscle content of G6P by 31P nuclear magnetic resonance during a hyperglycemic hyperinsulinemic clamp showed a decrease in both gastrocnemius muscle content of G6P and in nonoxidative glucose metabolism when compared with healthy control subjects. Although these studies measured G6P concentration rather than flux through the G6P pool, these findings may be consistent with a defect in glucose transport and/or phosphorylation inducing a secondary reduction in the rate of muscle glycogen synthesis (11) . Moreover, using a novel triple tracer technique in obese diabetic and nondiabetic patients, it has been demonstrated that transmembrane glucose transport and intracellular glucose phosphorylation in vivo are similarly impaired in skeletal muscle and may contribute to the insulin resistance found in these patients when compared with lean nondiabetic control subjects ( 12). However, the latter suggestions are challenged by the results from two other studies (13, 14) . When NIDDM patients and matched control subjects were examined during similar glucose utilization rates and similar circulating insulin levels, NIDDM patients had an increased intracellular concentration of free glucose and G6P in muscle tissue biopsies, indicating that the rate-limiting step in muscle glucose metabolism in patients with NIDDM under these experimental conditions may be located after G6P. Recently, a cDNA encoding human skeletal muscle HKII was cloned and sequenced (15, 16 (Table I) were seen between the group of NIDDM patients which was treated by diet alone and the group of patients which was treated with drugs. Before participation the purpose and risks of the study were carefully explained to all of the volunteers and their informed consent was obtained. The protocol was approved by the local Committee of Ethics in Copenhagen and was in accordance with the Helsinki Declaration.
Study protocol. All experiments were started in the fasting state at 0800 in the morning after a 10-h overnight fast. A venous blood sample was drawn and concentrations of plasma glucose, serum insulin, serum Cpeptide, plasma nonesterified fatty acids (NEFA), plasma triglycerides, and HbAlc were measured. Percutaneous muscle biopsies (-400 mg)
were obtained under local anesthesia (1% lidocaine without epinephrine) from the vastus lateralis muscle -20 cm above the knee, using a modified Bergstrom needle (Stille-Werner, Copenhagen, Denmark). Muscle samples were blotted to remove blood and connective and adipose tissue, and were within 30 s frozen in liquid nitrogen and stored at -800C until assayed.
Determination ofglycogen synthase (GS) and HK activities. Extraction of muscle samples (-50 mg), measurement of protein, and analysis of GS activity were performed as described previously ( 19) .
One aliquot of supernatant of muscle extracts was assayed in duplicate spectrophotometrically for total HK activity (HKI and HKII) in the presence of two concentrations of glucose (0.11 and 11.0 mmol/ liter) by a modification of the method of Easterby and Qadri (20) . The same initial supernatant used for the GS assay was used for HK assay except without dilution. Both for the GS and HK assays, Triton X-100 was included as a detergent to assay full enzyme activity. The supernatant was assayed at 220C in a buffer containing (final concentrations) 28 mmol/liter Tris-HCl (pH 7.6), 17.9 mmol/liter MgCl2, 2.8 mmol/ liter EDTA, 0.9 mmol/liter NADP', 0.6 mmol/liter ATP, and 13.8 mg/ ml G6P dehydrogenase (Boehringer Mannheim, Mannheim, Germany). The G6P produced in the HK reaction is coupled to G6P dehydrogenase. The reaction is followed by measuring the increase in absorbance at 340 nm due to NADPH formation. Another aliquot of supernatant from NIDDM patients and control subjects was heated for 60 min at 45°C in the absence of glucose and then assayed to assess heat-stable HK activity. Heat treatment results in the loss of -95% of HKII activity, whereas HKI activity is reduced by only 10% (2). In heat-treated samples, therefore, HKI activity is predominant. HKII activity was estimated as the difference between total HK and HKI activity.
Total HK, HKI, and HKII activities were expressed as nanomoles of glucose converted per minute per milligram of extracted protein.
Interassay coefficient of variation for total HK activity was 0.10 (n -6 separate experiments performed on muscle tissue from the same volunteer).
To exclude any influence of day-to-day variation, muscle samples from NIDDM patients and control subjects were prepared and analyzed for HK and GS enzyme activities pairwise at the same time.
Preparation of HKII antipeptide antibody. A peptide containing the nine-amino acid HKII carboxy terminus [(NHN2)-CRIREAGQR-COOH] was synthesized (Kem-En-Tec, Copenhagen, Denmark) and coupled to keyhole limpet hemocyanin using glutaraldehyde. 1 
Results
HK activity. Total HK as well as HKI activities were measured in muscle biopsies from the study participants. Muscle HKII activity was assessed as the difference between total and HKI activity. Using this approach we found that HKII activity was significantly decreased in NIDDM patients as assessed at both low (0.11 mmol/liter) and high ( 11.0 mmol/liter) glucose levels (P = 0.02 and 0.004, respectively) ( [NS] , NIDDM vs. control subjects). In muscle from NIDDM patients HKII represents 29±5% of total HK activity whereas in muscle from the control subjects HKII represents 41±5% (P = 0.08) at the low glucose level. At the highest glucose level comparable data were found, 31±4 and 47±7% (P = 0.02), NIDDM and control subjects, respectively. The increase in HK activity from 0.11 to 11.0 mmol/liter glucose was significant in NIDDM and control subjects for total HK, HKI, and HKII activities (P < 0.005 for all). However, the glucose-induced activation of HKII was significantly higher in the control subjects (P = 0.02) and a similar tendency to higher activation of HKI was also seen in the control group (P = 0.08). HKII activity as assessed at both low and high glucose levels was inversely correlated to both fasting plasma glucose (r = -0.45, P = 0.004 and r = -0.54, P < 0.0001) (Fig. 1) , plasma NEFA (r = -0.46, P = 0.003 and r = -0.37, P = 0.02) (Fig. 2) and HbAc (r = -0.33, P = 0.03 and r = -0.54, P < 0.0001) when estimated in the total group of study subjects (n = 40). GS activity. Total GS activity (i.e., in the presence c saturating concentration of the allosteric activator G6P) significantly higher in the group of control subjects (n = as compared with the group of NIDDM patients (n = when measured at the fasting serum insulin level (29.6±1.2 34.1 +±1.5 nmol/mg protein/min, P = 0.005, NIDDM vs. c trol, respectively).
HKII mRNA levels. The abundance of the specific H mRNA relative to human /-actin mRNA showed a four fivefold variation in vastus lateralis muscle within the grc of participants. In the basal state, HKII mRNA was significa decreased in the NIDDM patients when compared with (Fig. 3) . HKII mRNA levels were inversely correlated to both fasting plasma glucose (r = -0.73, P < 0.0001) (Fig. 4 A) , plasma NEFA (r = -0.60, P < 0.0001) (Fig. 4 B) , and HbA1c (r = -0.54, P < 0.0001) when estimated in the entire group of study participants (Fig. 4, A and B) (n = 40).
GS mRNA levels. Using the PCR technique, the abundance of GS mRNA relative to human /-actin mRNA was assessed from muscle biopsies taken in the basal period in a subgroup of 14 NIDDM patients and 14 control subjects. The GS mRNA was significantly decreased in the NIDDM patients (69+6 vs. HKII immunoreactive protein levels. The amount of HKII immunoreactivity in homogenates from vastus lateralis muscle was quantitated by immunoblotting using antipeptide antiserum specific for HKII. In all participants a dominant band of -100 kD was identified for HKII immunoreactive protein (Fig. 5 A) .
Densitometric scanning of autoradiograms showed significantly decreased levels of HKII protein in the entire group of NIDDM patients compared with the control group when results were normalized for equal amounts of protein (77+6 [ Fig. 5 B] ).
Expressing HKII enzyme activities in the groups of study participants relative to the HKII immunoreactive protein levels we found no differences in HKII activity between the NIDDM and control subjects, indicating that the decreased HKII enzyme activity in NIDDM patients may be due to a reduced level of HKH protein (data not shown). stabilities. Incubation at 450C for 60 min in the absence of glucose reduces HKI and HKII activity by -10 and -95%, respectively (2). In heat-treated samples, therefore, HKI is the predominant HK activity. Using this approach in supernatants of muscle homogenates from both NIDDM and control subjects examined in the fasting state we found that heath-stable HKI activity is normal in NIDDM whereas HKI activity represents a significantly higher percentage of total HK activity in NIDDM patients (-72%) when compared with the control subjects (-60%). This is clearly higher than what has been reported in diabetic and control rat (27, 28 ) and diabetic and control mouse (1, 29) skeletal muscle. However, previous studies using electrophoretic methods to assess the amount of specific HK proteins have found more HKI than HKII protein in human skeletal muscle (30, 31 ) , thus indirectly confirming our results.
In the NIDDM patients we found a significantly decreased muscle HKII activity. Cloning and sequencing of the HKH cDNA from human skeletal muscle (15, 32) made it possible to examine whether these functional abnormalities in glucose metabolism were accompanied by alterations in the pretranslational regulation of HKII. The level of basal HKII mRNA from skeletal muscle biopsies was measured using a PCR method (22) variant was widespread with an allelic frequency of 19% among control subjects and 17% among NIDDM patients. However, no obvious relationships between whole-body insulin sensitivity or glucose effectiveness and the gene variant could be shown. Thus, no gene defects were identified in the coding region which were likely to be related to an increased HKII mRNA degradation.
To determine whether reduced muscle glucose transport and/or phosphorylation is a primary defect in the pathogenesis of NIDDM, whole-body glucose uptake has been measured during a hyperglycemic hyperinsulinemic clamp in diabetes-prone but glucose-tolerant offspring of NIDDM patients and muscle G6P concentration was assessed using 31P NMR spectroscopy of gastrocnemius muscle (36) . Both G6P concentration and whole-body insulin-stimulated glucose uptake were significantly lower in the offspring when compared with a matched control group, suggesting reduced glucose transport and/or glucose phosphorylation as a cause of reduced glucose uptake and that this defect might be an early event in the pathogenesis of NIDDM. Whether muscle HKII gene expression is impaired in glucose-tolerant offspring of NIDDM patients still has to be clarified, whereas muscle GLUT4 gene expression has been shown to be normal (37) .
GS, which is the rate-determining enzyme in the muscle glycogen synthesis pathway, may be modified covalently by multiple phosphorylations of serine residues (38) . Insulin activates GS covalently by reducing and increasing the activities of specific kinases and phosphatase, respectively (39, 40), whereas G6P allosterically activates the phosphorylated form of GS (38) . The stimulatory effect of G6P at physiological concentrations on GS seems to be specific for GS and is most likely due to conformational changes of the enzyme which facilitates its dephosphorylation (41) . Whether the physiologic consequences of the changes in muscle HKII gene expression in NIDDM patients have any influence on the GS activation in vivo is, however, uncertain. Two previous investigations have shown that when NIDDM patients and matched control subjects were examined during similar glucose utilization rates and similar circulating plasma insulin levels (isoglycemic hyperinsulinemic clamp conditions), diabetic patients had an increased intracellular concentration of free glucose and G6P in muscle tissue, indicating that the rate-limiting step in muscle glucose metabolism during isoglycemic hyperinsulinemia in patients with NIDDM may be located distal to the glucose phosphorylation step (13, 14) . Also during fasting hyperglycemia NIDDM patients had increased levels of intracellular glucose and G6P, further indicating that the rate-limiting step in muscle glucose metabolism may be located distal to the glucose phosphorylation step ( 14) . These data were further supported from studies of three groups of either metabolically normal, insulin-resistant nondiabetic, or overtly diabetic rhesus monkeys showing that under euglycemic hyperinsulinemic conditions significantly inverse relations exist between intracellular G6P and GS activation and insulin-stimulated glucose uptake, indicating a major defect distal to G6P in these insulin-resistant and diabetic monkeys (42) . The insulin-resistant monkeys were also characterized by having increased levels of intracellular muscle G6P during euglycemic hyperinsulinemia. Whether the increase in intracellular glucose and G6P found in these studies may be extrapolated to the present protocol to suggest that glucose and its metabolite may have a downregulatory impact on HKII gene expression needs to be further investigated. Moreover, the finding that skeletal muscle glucose and G6P concentrations are 2644 Vestergaard et al.
T increased in NIDDM patients during either hyperglycemia or isoglycemic hyperinsulinemia does not exclude the possibility for decreased intracellular muscle glucose or G6P concentrations during euglycemia, which might point to an additional impairment in either glucose transport or phosphorylation. Data implying such defects have been published recently in a study using a novel triple tracer technique in obese diabetic and nondiabetic patients. During a euglycemic hyperinsulinemic clamp it was shown that transmembrane glucose transport and intracellular glucose phosphorylation in vivo are similarly impaired in skeletal muscle and may contribute to the insulin resistance found in these patients when compared with lean nondiabetic control subjects (12).
